Specialized CRO Cmed is a technology-led CRO with strong expertise in complex, innovative trials across oncology, cell & gene therapy, and rare diseases, presenting opportunities to upsell integrated data analytics, monitoring, and decentralized trial solutions to sponsors in these high-need areas.

Tech stack leverage With an in-house tech focus and tools like Power BI, AWS, Azure, Jira, Confluence, and Encapsia capabilities, there is a clear avenue to position Cmed as the preferred partner for scalable, cloud-based trial management, data capture, and analytics platforms.

Home/remote data Recent capabilities around encapsia and the Home Visit app indicate momentum in remote data capture and decentralized trial support, suggesting opportunities to expand into remote site management, patient monitoring, and at-home data collection services.

Growth readiness Revenue size and growth potential position Cmed as a mid-market CRO with ambitions to scale; sales discussions can emphasize flexible engagement models, accelerated study start-up, and technology-enabled efficiencies to win mid-to-large phase trials.

Strategic partnerships Past collaborations and a strong reputation in demanding trials create openings for strategic alliances with sponsor organizations seeking specialized expertise in oncology, gene therapy, and rare diseases, leveraging joint go-to-market and co-development opportunities.